512 results on '"Westerhout, Cynthia M."'
Search Results
2. Age, Sex, and Outcomes in Heart Failure With Reduced EF: Insights From the VICTORIA Trial
3. Abstract 14391: Biomarkers, Proteomics, and Echocardiography Lend Insights into Cardiovascular Death in HFrEF: A VICTORIA Substudy
4. Evolution of NT-proBNP During Prerandomization Screening in VICTORIA: Implications for Clinical Outcomes and Efficacy of Vericiguat
5. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial
6. Ejection Fraction, Biomarkers, and Outcomes and Impact of Vericiguat on Outcomes Across EF in VICTORIA
7. Assessment of Biomarkers of Myocardial injury, Inflammation, and Renal Function in Heart Failure With Reduced Ejection Fraction: The VICTORIA Biomarker Substudy
8. Patient-Reported Frailty and Functional Status in Heart Failure With Preserved Ejection Fraction: Insights From VITALITY-HFpEF
9. STREAM-2: Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment–Elevation Myocardial Infarction: A Randomized, Open-Label Trial
10. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes
11. Sequential Evaluation of NT-proBNP in Heart Failure: Insights Into Clinical Outcomes and Efficacy of Vericiguat
12. Abstract 11603: Comparing Analytical Methods for Composite Endpoints in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
13. Abstract 11574: Relationship Between Baseline Electrocardiographic Parameters and Outcomes in Patients With High-Risk Heart Failure With Reduced Ejection Fraction: Insights From the Vericiguat Global Study in Patients With Heart Failure With Reduced Ejection Fraction (VICTORIA) Trial
14. Abstract 11453: Age, Sex, and Outcomes in Heart Failure With Reduced Ejection Fraction: Insights From the VICTORIA Trial
15. N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes: Vericiguat Heart Failure With Reduced Ejection Fraction Study
16. Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.
17. Long-Term Outcomes of Complete Revascularization With Percutaneous Coronary Intervention in Acute Coronary Syndromes
18. Hemoglobin and Clinical Outcomes in the Vericiguat Global Study in Patients With Heart Failure and Reduced Ejection Fraction (VICTORIA)
19. Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study
20. Traveling the Interstices of Data Sharing
21. NT-PROBNP DURING SCREENING IN THE STUDY OF VERICIGUAT IN PARTICIPANTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (VICTORIA) TRIAL: INSIGHTS INTO OUTCOMES AND VERICIGUAT
22. Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study
23. Relationship between baseline electrocardiographic measurements and outcomes in patients with high‐risk heart failure: Insights from the VerICiguaT Global Study in Subjects with Heart Failure with Reduced Ejection Fraction (VICTORIA) trial.
24. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice: Insights From the Vital Heart Response Registry
25. The Titration and Tolerability of Sacubitril/Valsartan for Patients with Heart Failure in Clinical Practice
26. Effect of vericiguat on left ventricular structure and function in patients with heart failure with reduced ejection fraction: The VICTORIA echocardiographic substudy.
27. Relationship Between Time to Invasive Assessment and Clinical Outcomes of Patients Undergoing an Early Invasive Strategy After Fibrinolysis for ST-Segment Elevation Myocardial Infarction: A Patient-Level Analysis of the Randomized Early Routine Invasive Clinical Trials
28. Predictors and associated clinical outcomes of low cardiac output syndrome following cardiac surgery: insights from the LEVO-CTS trial
29. The association between meteorological events and acute heart failure: New insights from ASCEND-HF
30. Acute decompensated heart failure patients admitted to critical care units: Insights from ASCEND-HF
31. Dietary fatty acids intake and mortality in patients with heart failure
32. Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early After Myocardial Infarction [STREAM] Study)
33. The relationship between meteorological conditions and index acute coronary events in a global clinical trial
34. DOES FRAILTY MODULATE HEALTH STATUS IN PATIENTS WITH HEART FAILURE AND PRESERVED EJECTION FRACTION?
35. EJECTION FRACTION, BIOMARKERS, AND OUTCOMES IN HEART FAILURE WITH REDUCED EJECTION FRACTION AND THE IMPACT OF VERICIGUAT ON OUTCOMES IN THE VICTORIA TRIAL
36. Quantitative ST-depression in Acute Coronary Syndromes: the PLATO Electrocardiographic Substudy
37. Corrigendum to “Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the Strategic Reperfusion Early After Myocardial infarction trial” [Am Heart J 169/6 (2015) 890–898]
38. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial
39. Relative Prognostic Value of Baseline Q Wave and Time from Symptom Onset Among Men and Women With ST-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention
40. High-risk patients with ST-elevation myocardial infarction derive greatest absolute benefit from primary percutaneous coronary intervention: Results from the Primary Coronary Angioplasty Trialist versus Thrombolysis (PCAT)-2 Collaboration
41. The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST
42. Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolytic–3 (ASSENT-3) trial
43. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine
44. Novel multi-marker proteomics in phenotypically matched patients with ST-segment myocardial infarction: association with clinical outcomes
45. Participation in a Heart Failure Clinical Trial
46. Are International Differences in the Outcomes of Acute Coronary Syndromes Apparent or Real? A Multilevel Analysis
47. Implications of ischaemic area at risk and mode of reperfusion in ST-elevation myocardial infarction
48. Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial.
49. Consistency of benefit from an early invasive strategy after fibrinolysis: a patient-level meta-analysis
50. Is visual interpretation of coronary epicardial flow reliable in patients with ST-elevation myocardial infarction undergoing primary angioplasty? Insights from the angiographic substudy of the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX-AMI) trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.